These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


212 related items for PubMed ID: 9331009

  • 1. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
    Zanchetti A, Omboni S, Di Biagio C.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
    [No Abstract] [Full Text] [Related]

  • 2. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract] [Full Text] [Related]

  • 3. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 4. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
    Andersson OK, Neldam S.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S63-4. PubMed ID: 9331011
    [No Abstract] [Full Text] [Related]

  • 6. Role of the renin-angiotensin system in hypertension in the elderly.
    Nagano M, Higaki J, Mikami H, Ogihara T.
    Blood Press Suppl; 1994 Sep 11; 5():130-3. PubMed ID: 7889195
    [Abstract] [Full Text] [Related]

  • 7. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group.
    Tanser PH, Campbell LM, Carranza J, Karrash J, Toutouzas P, Watts R.
    Am J Hypertens; 2000 Feb 11; 13(2):214-8. PubMed ID: 10701823
    [Abstract] [Full Text] [Related]

  • 8. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
    Heuer HJ, Schöndorfer G, Högemann AM.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S55-6. PubMed ID: 9331008
    [No Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
    Sever P, Holzgreve H.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S69-73. PubMed ID: 9331014
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T, Arakawa K.
    J Hum Hypertens; 1999 Jan 11; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [Abstract] [Full Text] [Related]

  • 11. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.
    Zanchetti A, Omboni S.
    Am J Hypertens; 2001 Feb 11; 14(2):129-34. PubMed ID: 11243303
    [Abstract] [Full Text] [Related]

  • 12. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep 11; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 14. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
    Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, Redón J, Asmar R, Hedner T, Effect Study Group.
    Blood Press; 2001 Sep 11; 10(1):43-51. PubMed ID: 11332334
    [Abstract] [Full Text] [Related]

  • 15. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E, CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.
    J Hypertens; 2005 Feb 11; 23(2):435-44. PubMed ID: 15662233
    [Abstract] [Full Text] [Related]

  • 16. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr 11; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 17. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000 Apr 11; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT, O'Kane KP, Jonker J, Roth J.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [Abstract] [Full Text] [Related]

  • 19. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension.
    Philipp T, Letzel H, Arens HJ.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S67-8. PubMed ID: 9331013
    [No Abstract] [Full Text] [Related]

  • 20. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec 11; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.